Bavarian Nordic (LSE:0DPB) - Stock Price, News & Analysis

0DPB Stock Overview

Develops, manufactures, and commercializes life-saving vaccines.

0DPB fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	1/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 71.6% below our estimate of its fair value

Earnings are forecast to grow 5.71% per year

Earnings grew by 227.1% over the past year

Trading at good value compared to peers and industry

Risk Analysis

Large one-off items impacting financial results

Bavarian Nordic A/S Competitors

Genus

LSE:GNS

UK£1.1b

Bioventix

AIM:BVXP

UK£227.1m

HUTCHMED (China)

AIM:HCM

UK£2.4b

Ergomed

AIM:ERGO

UK£701.1m

Price History & Performance

Summary of all time highs, changes and price drops for Bavarian Nordic
Historical stock prices
Current Share Price	kr.157.30
52 Week High	kr.198.05
52 Week Low	kr.125.55
Beta	1.42
11 Month Change	-12.00%
3 Month Change	1.52%
1 Year Change	-20.03%
33 Year Change	-40.10%
5 Year Change	-4.50%
Change since IPO	-51.77%

Recent updates

Shareholder Returns

	0DPB	GB Biotechs	GB Market
7D	-0.6%	-0.6%	1.7%
1Y	-20.0%	-25.1%	8.9%

Return vs Industry: 0DPB exceeded the UK Biotechs industry which returned -25.1% over the past year.

Return vs Market: 0DPB underperformed the UK Market which returned 8.9% over the past year.

Price Volatility

Is 0DPB's price volatile compared to industry and market?
0DPB volatility
0DPB Average Weekly Movement	4.0%
Biotechs Industry Average Movement	6.2%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.2%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: 0DPB has not had significant price volatility in the past 3 months.

Volatility Over Time: 0DPB's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1992	1,381	Paul Chaplin	www.bavarian-nordic.com

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2.

Bavarian Nordic A/S Fundamentals Summary

How do Bavarian Nordic's earnings and revenue compare to its market cap?
0DPB fundamental statistics
Market cap	kr.12.22b
Earnings (TTM)	kr.984.37m
Revenue (TTM)	kr.6.64b

12.4x

P/E Ratio

1.8x

P/S Ratio

Is 0DPB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0DPB income statement (TTM)
Revenue	kr.6.64b
Cost of Revenue	kr.2.04b
Gross Profit	kr.4.60b
Other Expenses	kr.3.62b
Earnings	kr.984.37m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 22, 2024

Earnings per share (EPS)	12.65
Gross Margin	69.29%
Net Profit Margin	14.82%
Debt/Equity Ratio	0.2%

How did 0DPB perform over the long term?

See historical performance and comparison

0DPB Stock Overview

Rewards

Risk Analysis

Bavarian Nordic A/S Competitors

LSE:GNS

UK£1.1b

AIM:BVXP

UK£227.1m

AIM:HCM

UK£2.4b

AIM:ERGO

UK£701.1m

Price History & Performance

Recent News & Updates

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

New minor risk - Earnings quality

Recent updates

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

New minor risk - Earnings quality

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Investor sentiment improves as stock rises 16%

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 26%

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Now 21% undervalued

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold kr.508k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: kr.0.20 (vs kr.1.30 loss in 3Q 2021)

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Second quarter 2022 earnings released: kr.3.40 loss per share (vs kr.2.40 loss in 2Q 2021)

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

First quarter 2022 earnings released

Now 41% undervalued

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Less than half of directors are independent

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial